Vanderbilt Vaccine Research Program

June 4, 2020

Remdesivir helps reduce COVID-19 recovery time: study

The investigational antiviral drug remdesivir can shorten the time to recovery in adults hospitalized with COVID-19, according to preliminary results of a clinical trial published last month in The New England Journal of Medicine.

By Bill Snyder
April 29, 2020

Vanderbilt investigators encouraged by early results of placebo-controlled remdesivir trial

A preliminary look at data from hospitalized adults diagnosed with coronavirus disease 2019 (COVID-19) in a randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir is showing promising results.

By Craig Boerner
Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.
February 5, 2020

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program has received a grant from the NIH to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units.

By Bill Snyder
Vials with medication and syringe on blue methacrylate table. Horizontal composition. Top elevated view.
January 23, 2020

Vaccine Program receives NIH renewal of VTEU

The Vanderbilt Vaccine Research Program (VVRP) has received a grant from the National Institutes of Health (NIH) to continue its work as one of the nation’s nine Vaccine and Treatment Evaluation Units (VTEUs).

By Bill Snyder
Man holds his hand over his mouth while coughing into it
January 28, 2019

Nasal whooping cough vaccine trial underway at Vanderbilt

Vanderbilt vaccine researchers are enrolling adult volunteers in a National Institutes of Health (NIH)-sponsored Phase II clinical trial that will study a next generation pertussis vaccine that may protect people from whooping cough.

By Craig Boerner
November 1, 2018

Team seeks to identify immune response to influenza

Vanderbilt researchers, as part of the International Human Vaccines Project, are searching for the key to lasting protection against influenza by examining naturally protecting cells found in bone marrow.

By Craig Boerner
March 15, 2018

Volunteers sought for bird flu vaccine trial

Vanderbilt University Medical Center is recruiting volunteers to participate in a national study of an investigational vaccine against the H7N9 influenza virus, also known as “bird flu.”
By Bill Snyder
October 26, 2017

Vanderbilt leads international effort to develop universal flu vaccine

Researchers at Vanderbilt University Medical Center are leading an international effort to develop a universal influenza vaccine that would protect everyone against all strains of the flu anywhere in the world.
By Bill Snyder
July 13, 2017

New approach for staph-related skin abscesses explored

New multicenter research that includes Vanderbilt University Medical Center (VUMC) investigators, could change treatment approaches to simple skin abscesses, infections often caused by Staphylococcus aureus (staph) bacteria.
By Christina Echegaray
December 1, 2016

Study tests shorter antibiotic course in children

Researchers at Vanderbilt University Medical Center (VUMC) are leading a multicenter clinical trial to evaluate whether a shorter course of antibiotics — five days instead of 10 — is effective at treating community-acquired pneumonia (CAP) in children who show improvement after the first few days of taking antibiotics.
By Christina Echegaray
October 19, 2015

Two Ebola Survivors’ Blood Could Help Vanderbilt Researchers Find A Treatment

By VUMC News and Communications
October 8, 2015

Creech to direct Vanderbilt Vaccine Research Program

Buddy Creech, M.D., MPH, associate professor of Pediatrics, has been named director of the Vanderbilt Vaccine Research Program (VVRP) in the Division of Pediatric Infectious Diseases.
By VUMC News and Communications
April 8, 2015

VU joins national effort to speed Ebola therapy testing

Vanderbilt University researchers have joined a multi-center effort led by Pennsylvania-based Inovio Pharmaceuticals Inc. to accelerate development of potential antibody therapies against the often-lethal Ebola virus.
By Bill Snyder
1 2 3